You are here
ALLTRANZ, INC.
UEI: EKBZRSBPS8A3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Transdermal Naltrexone for Opiate Addiction and Alcoholism
Amount: $695,993.00DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and ...
STTRPhase II2014Department of Health and Human Services National Institutes of Health -
Transdermal Naltrexone for Opiate Addiction and Alcoholism
Amount: $537,779.00DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and ...
STTRPhase I2012Department of Health and Human Services National Institutes of Health -
Transdermal Cannabidiol Prodrug Delivery
Amount: $160,500.00DESCRIPTION (provided by applicant): With over 8.5% of the U.S. population and 75 million people worldwide meeting the diagnostic criteria for alcohol use disorders (AUDs), alcohol abuse is among the ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Transdermal Delivery of Buprenorphine Prodrugs
Amount: $115,025.00DESCRIPTION (provided by applicant): Currently buprenorphine (BUP) is used in the treatment of opioid abuse and for pain management. It can also be used improperly and abused as an opioid. In the Unit ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Transdermal Cannabidiol Delivery for Alcohol-Induced Neurodegeneration
Amount: $100,565.00DESCRIPTION (provided by applicant): Treatment of alcohol use disorders (AUDs), commonly referred to as alcoholism, has been hampered by alcohol's promiscuous pharmacological effects and the complex e ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health
